NMDA antagonists
Articles tagged with “NMDA antagonists”
NMDA Side Effects: What the Data Means for Troche Users
New research on NMDA antagonist side effects and discontinuation rates offers practical guidance for ketamine troche patients managing treatment-resistant depression.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.
Ketamine Side Effects: What New Data Means for Troches
New 2026 NMDA-antagonist data on troche side effects and discontinuation rates: how ketamine troches compare on safety and tolerability vs other formats.
NMDA Antagonist Side Effects: What Troche Users Should Know
New research compares side effect profiles and dropout rates across NMDA antagonists. Here's what it means for ketamine troche patients in 2026.
NMDA Antagonist Side Effects: What Troche Users Need to Know
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients. Here's what it means for your treatment.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.